Heart Metabolics

Pharmaceutical therapy for the treatment of hypertrophic cardiomyopathy (“HCM”).

placeLondon, England, United Kingdom calendar_todayFounded 2013 groups4 employees language heartmetabolics.com

Registered entities

Innovation

8 patent families (3 granted) — focus: Human necessities; filing pace dormant. Cited 1,130 times.

YearFilings
20123
20132
20142
20153
20162
20172
20191

Investor mix

12 investors on record; lead investors include AshHill, ttcf.com.au, VenBio, Seroba Life Sciences.

Investor typeCountShare
Venture capital433%
Bank & private debt18%
Other / undisclosed758%
Coming soon